Zhejiang Jianfeng Group's wholly-owned subsidiary has obtained a drug registration certificate.

Zhejiang Jianfeng Group (600668.SH) announcement, recently, the company's wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as "Jianfeng Pharmaceutical") received the approval and issuance of the Drug Registration Certificate for Rosartan Capsules by the National Medical Products Administration [Certificate Numbers: 2025S00631 (20mg); 2025S00632 (50mg)]. Rosartan Capsules are used for the treatment of anemia caused by chronic kidney disease (CKD), including patients on dialysis and non-dialysis patients.